CORT - Corcept Therapeutics Incorporated
FAS Wealth Partners Inc. increased its stake in Corcept Therapeutics Incorporated (NASDAQ: CORT) by 4.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 322,370 shares of the biotechnology company's stock after buying an additional 12,352 shares during
Avidity Partners Management LP lifted its stake in Corcept Therapeutics Incorporated (NASDAQ: CORT) by 36.4% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 30,000 shares of the biotechnology company's stock after buying an additional 8,000 shares during the period.
Corcept Therapeutics remains a 'Hold' as LIFYORLI's strong launch and clinical demand are already reflected in a premium valuation. LIFYORLI generated $47.6M in its first full quarter, with management targeting $1B+ US peak revenue and global NPV estimated at $4.24B. CORT's pipeline offers upside, notably with relacorilant in earlier PROC lines and EU approval pending, but non-LIFYORLI assets remain speculative.
Corcept tops Q2 earnings estimates as Korlym growth and a strong Lifyorli launch lift revenues, prompting a higher 2026 top-line outlook.
Corcept Therapeutics Incorporated (CORT) Q2 2026 Earnings Call Transcript
Corcept Therapeutics (CORT) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to earnings of $0.29 per share a year ago.
Corcept Therapeutics NASDAQ: CORT reported second-quarter 2026 revenue of $256.1 million, up 32% from the prior-year period, as sales from its Cushing's syndrome franchise increased and its newly launched ovarian cancer therapy LIFYORLI contributed $47.6 million in its first quarter of availability.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended June 30, 2026. Financial Results “Our oncology and Cushing's syndrome businesses delivered strong results in the second quarter. In our oncology busi.
Here is how Corcept Therapeutics (CORT) and Quest Diagnostics (DGX) have performed compared to their sector so far this year.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on July 29, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).Conference Call InformationParticipants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access PIN.
President Donald Trump has announced that all generic drugs imported into the United States would continue to enjoy a zero-percent tariff for another two years, sending major drug stocks up.
FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approach offers lower costs and steadier performance.
The transaction involved 40,000 shares with an estimated value of $3.5 million on the July 15, 2026 transaction date. The activity was executed through the conversion of 40,000 options at $19.26 and $23.06 per share, which were immediately liquidated.
The transaction involved the sale of 10,000 shares at $88.30 per share, resulting in a total value of $883,000 on July 15, 2026. The sale reduced the insider's total indirect equity holdings by 0.67%.
The transaction realized $1.9 million in gross proceeds on July 7, 2026, at a weighted average price of $93.13 per share. The disposition was a cashless exercise of 20,000 options at a strike price of $21.65, followed by an immediate open-market sale.
Corcept Therapeutics maintains a Buy rating, supported by robust revenue growth, pipeline progress, and strong management execution. Relacorilant's FDA approval in ovarian cancer and likely approval in Cushing's syndrome could drive CORT revenues above $3 billion annually by decade's end. 2026 revenue guidance of $950M–$1.05B reflects >30% YoY growth, with minimal impact expected from generic competition due to pipeline innovation.
Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday's close, to $83.54 earlier today.
NEW YORK, June 25, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Corcept Therapeutics Incorporated (NASDAQ: CORT) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Corcept Therapeutics Incorporated failed to disclose adverse facts concerning potential FDA approval of one of the Company's lead new product candidates, relacorilant, a medication being developed for multiple indications, including the treatment of hypercortisolism, or Cushing's syndrome.
CORT resubmits relacorilant NDA for Cushing's syndrome, with updated analyses and data from multiple clinical studies supporting the filing.
NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Corcept Therapeutics Incorporated (NASDAQ: CORT) breached their fiduciary duties to shareholders.